Approval of ACIP Recommendations for Use of the FDA-Approved Pfizer-BioNTech COVID-19 Vaccine

Approved by the Executive Committee of the Board of Regents on Sept. 1, 2021

Background:

Each year, the Advisory Committee on Immunization Practices (ACIP) reviews and publishes the recommended adult immunization schedule for adults aged 19 and older. In November 2020, the Executive Committee of the Board of Regents (ECBOR) approved the 2021 ACIP Recommended Immunization Schedule for Adults, which was published in *Annals* in March 2021. The ECBOR has also voted to support interim ACIP recommendations for use of Pfizer-BioNTech, Moderna, and Janssen COVID-19 vaccines under the FDA’s Emergency Use Authorization (EUA), as well as recommendations for use of an additional dose of mRNA COVID-19 vaccine among immunocompromised people.

The ACIP convened a meeting on August 30, 2021 to review and vote on recommendations for use of the FDA-approved Pfizer-BioNTech (COMIRNATY) COVID-19 Vaccine in persons aged ≥16 years. ACIP voted unanimously to approve the following recommendation:

*The Pfizer-BioNTech COVID-19 vaccine is recommended for people 16 years of age and older under the FDA’s Biologics License Application (BLA) approval.*

ACP’s Immunization Committee (IC) convened on Wednesday, September 1, 2021, by video conference to discuss the new ACIP recommendation. IC members in attendance included Vidya Sundareshan, MD, FACP (Chair); Jason Goldman, MD, FACP; Saba Hasan, MD, FACP; Susan Lee, MD, FACP; and Kristin Mitchell, MD, FACP.

IC members in attendance voted unanimously to support the new ACIP recommendations. IC members Michael Bronze, MD, MACP and Josune Iglesias, MD, FACP were unable to attend the meeting.

The IC recommends that the ECBOR support ACIP recommendations for use of the Pfizer-BioNTech COVID-19 vaccine for people 16 years of age and older under the FDA’s BLA approval.